George Derbin
Publications by Year
Research Areas
Angiogenesis and VEGF in Cancer, Drug Solubulity and Delivery Systems, HER2/EGFR in Cancer Research, Helicobacter pylori-related gastroenterology studies, Microfluidic and Capillary Electrophoresis Applications
Most-Cited Works
- → Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)(2008)141 cited
- → Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an In Vivo Active Potent VEGFR-2 Inhibitor(2006)132 cited
- → Discovery and Evaluation of N-Cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a Selective and Orally Efficacious Inhibitor of Vascular Endothelial Growth Factor Receptor-2(2006)40 cited
- → Development of a Canine Model to Enable the Preclinical Assessment of Ph-dependent Absorption of Test Compounds(2011)29 cited
- → Circumvention of pH-dependent release from ethylcellulosecoated pellets(1995)20 cited
- → Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor(2008)19 cited
- → Role of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug(2015)16 cited
- → Acid-Catalyzed Hydrolysis of BMS-582664: Degradation Product Identification and Mechanism Elucidation(2011)6 cited
- → Food Increased the Bioavailability of BMS‐690514, an Orally Active EGFR/HER2/VEGF Receptor Kinase Inhibitor, in Healthy Subjects(2011)5 cited